Helius Medical Technologies Inc announces the addition of Shepherd Center in Atlanta to its Therapeutic Experience Program (TEP). This initiative will be led by Deborah Backus, PT, PhD, FACRM, Vice President of Research and Innovation and Director of Multiple Sclerosis Research at the Virginia C. Crawford Research Institute at Shepherd Center.
Shepherd Center joins NYU Langone Health as the second Center of Excellence in this company-sponsored open-label observational trial designed to evaluate the impact of subjects’ adherence to Portable Neuromodulation Stimulator (PoNS) therapy in patients with multiple sclerosis (MS).
“Our Therapeutic Experience Program enables clinicians to evaluate the effectiveness of PoNS therapy for MS patients with gait deficit in a real-world environment while providing important information about PoNS therapy to key opinion leaders in MS management,” said Antonella Favit-Van Pelt, MD, PhD, Helius’ Chief Medical Officer.
“The Virginia C. Crawford Research Institute at Shepherd Center is an important partner to TEP, and we are thrilled with Dr. Backus’s contribution to our efforts of bringing innovative therapies to people with MS. Shepherd Center is one of the top ten rehabilitation hospitals in the United States with a world-renowned Multiple Sclerosis Institute and integrated research program, and we look forward to a long-standing collaboration.”
“Shepherd Center is dedicated to improving the function, health, and quality of life in all people with MS, and we are excited to partner with Helius on this important study,” Backus says. “People with MS often have decreased mobility, leading to more disability and less participation in daily life activities. We believe PoNS therapy can be an effective therapeutic option for our patients.”
[Source(s): Helius Medical Technologies Inc, GlobeNewswire]
